COVID-19 prophylaxis with immunoglobulin Y (IgY) for the world population: The critical role that governments and non-governmental organizations can play
J Glob Health
.
2022 Dec 3:12:03080.
doi: 10.7189/jogh.12.03080.
Authors
Lyn R Frumkin
1
,
Michaela Lucas
2
,
Michael Wallach
3
4
,
Curtis L Scribner
5
,
Tom St John
1
,
Daria Mochly-Rosen
1
6
7
Affiliations
1
SPARK at Stanford, Stanford University, School of Medicine, Stanford, California, USA.
2
Medical School, The University of Western Australia, Perth, Western Australia, Australia.
3
University of Technology Sydney, Sydney, New South Wales, Australia.
4
SPARK Sydney, Sydney, New South Wales, Australia.
5
Independent Regulatory Consultant, Oakland, California, USA.
6
Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, California, USA.
7
SPARK Global, Stanford University, School of Medicine, Stanford, California, USA.
PMID:
36462205
PMCID:
PMC9719602
DOI:
10.7189/jogh.12.03080
No abstract available
MeSH terms
COVID-19* / prevention & control
Government
Humans
Immunoglobulins
Substances
IgY
Immunoglobulins